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An elevated heart rate is a marker of cardiovascular risk in patients with stable coronary artery disease.
Ivabradine selectively inhibits the “f” current in the sinus node and reduces heart rate without any
modifications of blood pressure, myocardial contractility and arteriolar resistance. However the addition
of ivabradine to standard therapy to reduce heart rate did not improve outcomes in the recent SIGNIFY
trial. Moreover, a significant interaction between the effect of ivabradine among subgroups with and
without angina was detected, with a worse outcome in patients in CCS class >II at baseline. The
explanation for this surprising finding despite a significant reduction in angina and myocardial revas-
cularization procedures is uncertain. A J-curve for heart rate was not demonstrated. We speculate a
significant interference on adverse events (mainly atrial fibrillation and consequently acute coronary
syndromes) and on the outcome of unfavorable interactions between ivabradine and diltiazem, verap-
amil and strong inhibitors of CYP3A4 (4.6% of the total population).
Indeed, when these patients are excluded from subgroup analysis, the harmful effect of Ivabradine
among patients with severe angina disappears.
In conclusion, heart rate is a marker of risk but is not a risk factor and/or a target of therapy in patients
with stable coronary artery disease and preserved ventricular systolic function. Standard doses of
ivabradine are indicated for treatment of angina as an alternative or in addition to beta-blockers, but
should not be administered in association with CYP3A4 inhibitors or heart rate-lowering calcium-
channel blockers.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
A high resting heart rate (HR) is a marker of risk in patients with
heart failure [1], asymptomatic left ventricular systolic dysfunction
[2], stable coronary artery disease [3], and in subjects with car-
diovascular risk factors [4]. Indeed, an increase of HR determines
several pathophysiological changes leading to adverse cardiac
events: endothelial dysfunction and increase of oxidative stress,
plaque instability, increased myocardial oxygen consumption,
reduction of diastole duration with consequent reduction ofExperimental Diagnostic and
of Bologna, Via G. Massarenti
fabio.vagnarelli2@unibo.it
r Inc. This is an open access articlecoronary perfusion, remodeling and hypertrophy of left ventricle,
reduction of left ventricular filling duration, and decrease of
myocardial contractility [1e5]. By counteracting these unfavorable
mechanisms, HR pharmacological modulation may improve
symptoms and outcome.
Ivabradine selectively inhibits the “f” current in the sinus node
[6] and reduces the heart rate in a “pure” way, without any modi-
fications of blood pressure, myocardial contractility and arteriolar
resistance. Because of these pharmacological properties, imple-
mentation of ivabradine to standard therapy was tested in several
randomized trials to assess its effects through the cardiovascular
continuum.
In chronic heart failure (HF) secondary to left ventricular systolic
dysfunction (LVSD), the addition of ivabradine to standard therapy
improves symptoms and outcome: in SHIFT study primary com-
posite endpoint (cardiovascular death or hospital admission forunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Hazard ratios and 95% confidence interval for the primary endpoint (composite
of death from cardiovascular causes or nonfatal MI) in the overall population and in
prespecified angina subgroups in SIGNIFY trial.
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(NNT 24). These effects were strictly related to baseline (pre-
treatment) heart rate and to the extent of heart rate reduction after
4 weeks of therapy [1,5,7,8].
In the setting of coronary artery disease (CAD) with asymp-
tomatic LVSD and HR > 70 bpm, ivabradine reduces the rate of
hospitalization for fatal and non fatal MI, particularly in patients
suffering from angina [9].
In patients with symptomatic CAD and preserved left ventric-
ular function (PLVEF), ivabradine proved to be as effective as beta-
blockers to achieve adequate control of angina(10). Moreover,
ivabradine in combinationwith beta-blockers has shown a superior
anti-anginal and anti-ischemic effect during stress test, compared
to beta-blockers alone [11].
However, it was unknown whether reducing HR by ivabradine
on top of standard therapy improves outcome of patients with
stable CAD and PLVEF [12,13]. Therefore, the SIGNIFY study was
designed and performed to test this hypothesis [14].
2. Rationale and methodology
The SIGNIFY study was conducted to verify a very ambitious
hypothesis: reducing cardiovascular mortality and MI (fatal or not)
of patients with stable CAD and without clinical HF, through a pure
HR modulation with Ivabradine on top of current standard therapy
(including statins, antiplatelet drugs, ACE-inhibitors, beta-
blockers).
The research hypothesis was that lowering HR below 60 bpm
could reduce myocardial ischemia, myocardial oxygen consump-
tion, endothelial dysfunction, and oxidative stress.
A rigorous methodology was used by investigators to reach this
ambitious goal: 19,102 patients aged >55 years, who had both
stable CAD without clinical HF and a HR of 70 bpm or more, were
randomly assigned to placebo or ivabradine, at a dose of 7.5 mg up
to 10 mg twice daily, with the dose adjusted to achieve a target HR
of 55e60 beats per minute. Participants had to be in sinus rhythm,
have a resting heart rate of 70 beats per minute or more on two
consecutive electrocardiograms (during “run-in” period), and have
documented CAD or myocardial ischemia. Patients with left ven-
tricular dysfunction (left ventricular ejection fraction 40%) were
excluded.
Patients aged> 75 years were treated with 5 mg twice daily and
this dose was also used in case of excessive HR reduction with the
high dose.
The study included 12,049 patients (63%) with activity-limiting
angina [classII on the Canadian Cardiovascular Society scale). This
was a prespecified group in which the extent of the symptoms did
suggest a worse prognosis.
The primary end point was a composite of death from cardio-
vascular causes or nonfatal myocardial infarction. The secondary
end points included the components of the primary end point
(death from cardiovascular causes and nonfatal myocardial infarc-
tion) as well as death from any cause.
The mean age of the study populationwas 65 years, 72.4% of the
patients were men, and the mean resting HR was 77.2 beats per
minute. There was no evidence of left ventricular systolic
dysfunction in the overall study population (mean ejection fraction,
56.4%).
Most patients were receiving appropriate therapy for cardio-
vascular disease (beta-blockers in 83.1%, statins in 92.2%, anti-
platelet therapy or anticoagulants in 97.7% of the patients, and ACE
inhibitors in 59.3%)
According to the study protocol, 51% of patients were treated
with ivabradine 10 mg twice daily, 27% with 7.5 mg twice daily, 22%
with 5 mg twice daily.3. Main findings
Ivabradine reduced mean HR by 10 bpm compared to placebo
(at 3 months 60.7 ± 9.0 beats per minute with ivabradine and
70.6 ± 10.1 beats per minute with placebo). The difference in the
mean heart rate between the ivabradine group and the placebo
group was maintained for the duration of the study in the total
population and in the subgroup of patients with activity-limiting
angina at baseline. 30% of patients treated with ivabradine
reached a heart rate <50 bpm.
The rates of permanent discontinuation of the study drug were
20.6% in the ivabradine group and 14.5% in the placebo group
(p < 0.001).
The main reason for study-drug withdrawal in the ivabradine
group was asymptomatic bradycardia and, to a lesser extent,
symptomatic bradycardia. A higher incidence of bradycardia-
dependent atrial fibrillation was found in the ivabradine group
compared to placebo (5.3 vs. 3.8%; p < 0.01).
There was no significant difference in the incidence of the pri-
mary end point (composite of death from cardiovascular causes or
nonfatal MI) between the ivabradine group and the placebo group
(6.8% and 6.4%, respectively; hazard ratio, 1.08; 95% confidence
interval [CI], 0.96 to 1.20; P ¼ 0.20; Fig. 1). Moreover, there were no
significant between-group differences in any other secondary end
points.
Subgroup analysis showed only one significant interaction
(P¼ 0.02) between the study treatment and the presence of angina
at baseline in the prespecified subgroup defined according to CCS
class (P ¼ 0.02), with opposite findings among subgroups of pa-
tients without angina (or CCS I) and those with CCS IIeIV angina
(Fig. 1). Ivabradine was associated with a modest albeit significant
increase in the incidence of the primary end point among patients
who had angina of CCS class II or higher (7.6%, vs. 6.5% with pla-
cebo; hazard ratio, 1.18; 95% CI, 1.03 to 1.35; P ¼ 0.02) but not
among patients without angina or those who had angina of class I
(hazard ratio, 0.89; 95% CI, 0.74 to 1.08; P ¼ 0.25).
In contrast to the distribution of coronary events, a significant
improvement of angina (24.8% in ivabradine, 19.4% in placebo,
D ¼ 5.4%; p < 0.01) and a significant reduction of elective
myocardial revascularization (ivabradine 2.8%, placebo 3.5%,
D ¼ 0.7%, HR 0.82; p < 0.01) were found in the subgroup with CCS
IIeIV angina (Fig. 2). In the subgroup of patients with CCS IIeIV
angina treated with ivabradine, the main determinant of the
negative outcome was an increase of non-fatal MI (HR 1.18, 95% CI
0.97e1.42; p ¼ 0.09).
Fig. 2. Effects of Ivabradine vs. Placebo on angina control and coronary
revascularization.
Fig. 3. Determinants of prognosis in stable Coronary Artery Disease: a complex
interplay between clinical, anatomical, functional, and pathophysiological factors.
Fig. 4. Relationship between “on treatment” heart rate and major adverse cardiac
events (MACE) in Angina patients (Ivabradine Group). HR: hazard ratio. CI: confidence
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The SIGNIFY trial provides several pathophysiological
implications.
Firstly, the results of the study clearly show that HR is a risk
marker but not a risk factor in patients with CAD and PLVEF
receiving appropriate background therapy (ACE inhibitors, statins
and antiplatelet agents platelet). HR reduction in a population like
that, who is “a priori” at relatively low risk (2.8%/year) thanks to
current standard treatment, did not increase plaque stability; thus,
the hypothesis that HR itself may determine coronary events was
denied in the contemporary era of extensive antithrombotic/statin
therapy.
Secondly, the hypothesis that reducing ischemia and angina
may improve the prognosis was gainsaid too; actually, this result is
not a complete surprise. In patients with stable CAD and normal
ejection fraction, no drug among those used for symptom relief
(including beta-blocker) has proved to ameliorate prognosis [15].
Indeed, in current European guidelines these drugs are consistently
regarded as treatments aimed at improving symptoms, not prog-
nosis [16]. Even myocardial revascularization with angioplasty,
which represents the most effective treatment for angina [17], was
not able to improve outcome in COURAGE study [18], except for
patients with severe angina and/or ischemia.
Indeed, prognosis of patients with stable CAD is affected by
several factors (Fig. 3); the complex interplay between ischemia,
coronary vessel disease, functional components, and clinical pa-
rameters implies that a single pharmacologic intervention has little
chance to be effective, unless it acts on factors with a pivotal role in
the cascade leading to coronary events, such as plaque stability
(statins) or thrombosis (antiplatelets drugs).
However, the crucial “issue” within SIGNIFY study remains the
highest frequency of adverse events, mainly non fatal MI, in the
subgroup of patients with severe angina; among these, ivabradine
treatment was associated with a reduction of revascularization and
a substantial improvement of symptoms, but also with a worse
outcome, whereas ivabradine determined a non significant trend
towards better outcome in patients without angina.
The explanation of this surprising finding is uncertain, although
it should be treated with caution since the results of the primary
efficacy analysis were not significant. Whenever, in clinical trials,
opposite effects occur in subgroups of patients, it is also mandatory
to look for possible mechanisms underlying them. Indeed, they
may also be “spurious” or the result of chance. A possiblemechanism could stem from excessive bradycardia with subse-
quent reduction of coronary perfusion in patients with a greater
extent of coronary artery lesions.
However findings from an analysis performed by the Pharma-
covigilance Risk Assessment Committee of European Medicines
Agency (EMA) exploring the relationship between “on treatment”
Heart rate and outcome are against this hypothesis [19]. The main
results of EMA post-hoc analysis focused on patients with angina
and treated with ivabradine are summarized in Fig. 4: the lowest
number of MACE occurred in patients with heart rate 40e50 bpm,
the highest frequency of MACE was found among patients with
HR > 70 bpm, whereas a slight but not statistically significant in-
crease of MACE was detected in patients with HR < 40 bpm. In
addition Cox-regression analysis did not show an excess risk
associated with lower HR. Thus, the lack of a “J curve” and of a closeinterval.
Fig. 6. Theoretical relationship between the dose of a drug and the response (in terms
of clinical efficacy and toxic effect).
Fig. 7. Primary end-point occurrence in angina subgroup analysis of SIGNIFY Trial. A:
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other mechanism may be operating [14,19].
The use of ivabradine “unusual” doses (51% of patients received
10 mg twice daily) has certainly contributed to the development of
side effects, which were significantly higher in SIGNIFY than any
other clinical trials with ivabradine. Accordingly, most primary
endpoints occurred at the highest dose (57.7%) compared to the
7.5 mg (26.4%) and 5 mg (15.9%), with similar results for the indi-
vidual endpoints (Fig. 5).
For all drugs, increasing the dose increases the likelihood of side
effects, proportionally to the plasma levels of the drug itself (Fig. 6).
In addition, other mechanisms seem to have contributed to an
unpredictable increase of ivabradine plasma levels and conse-
quently to side effects. Within SIGNIFY study population, 1135
enrolled patients were treated also with diltiazem or verapamil,
and 262 were taking strong CYP3A4 inhibitors, which increase
ivabradine plasma levels. In the overall study population, this
pharmacological interactions were associated with a worse
outcome, both for the primary endpoint (risk increased by 43%,
interaction p-value ¼ 0.062) and for non-fatal MI (risk increased by
64%, interaction p-value ¼ 0.006). As mentioned above, when the
overall population of SIGNIFY trial is considered, a statistically
significant interaction is detected between subgroups with or
without severe angina. However, when patients receiving Diltia-
zem/Verapamil or strong CYP3A4 inhibitors are excluded from
analysis, the difference between groups (with or without severe
angina) and the harmful effect of Ivabradine among patients with
severe angina disappear (Fig. 7). The increased frequency of
nonfatal MI, which is the main “driver” of the unfavorable effect
found in ischemic subgroup, can be partially explained by the
higher frequency of atrial fibrillation (þ1.5%, p < 0.001) in the
ivabradine group [20], due to a bradycardia-dependent mechanism
(in particular for patients treated with verapamil/diltiazem, or
CYP3A4 inhibitors). Indeed, atrial fibrillation, when occurring in
patients with angina (CCS IIeIV) and severe CAD, may easily lead to
chest pain, ECG abnormalities and/or troponin increase with sub-
sequent non fatal MI.When the overall population is considered, a statistically significant interaction is
detected between subgroups with or without severe angina. B: When patients
receiving Diltiazem/Verapamil (1135) or strong CYP3A4 inhibitors (262) are excluded
from analysis, the difference between groups and the harmful effect of Ivabradine
among patients with severe angina disappear.5. Clinical implications
SIGNIFY may be considered a pathophysiological study, con-
ducted with a “strict” methodology, according to which more thanFig. 5. Distribution of primary endpoint occurrence according to Ivabradine dose. The
10 mg bid dose is not approved by European Medicines Agency (EMA).half patients in the ivabradine group (51%) received doses not
approved for clinical use by regulatory agencies. In addition, a small
but not negligible subgroup of patients (4%) was treated with drugs
not recommended to be used in combination with ivabradine
(among these the frequency of adverse events doubled). Lastly, the
management of patients suffering from severe angina (CCS> II)
with medical therapy alone does not reflect current clinical prac-
tice; in this clinical context, ESC guidelines recommend coronary
angiography and myocardial revascularization to improve symp-
toms [15]. Similarly to other studies conducted with a methodology
which is not usual in clinical practice, it is difficult to draw con-
clusions that are valid for the clinician.
However, SIGNIFY study may provide some clinical
implications:
1 HR modulation with ivabradine has no prognostic impact but it
may be useful for symptoms relief, as already shown by previous
studies [10,11]. ESC guidelines on stable CAD recommend ivab-
radine for this purpose indeed [15].
2 In patients with stable angina, ivabradine should be used as an
alternative to beta-blockers (if contraindicated or not tolerated)
or in combinationwith them. The recommended starting dose is
G.P. Perna et al. / Contemporary Clinical Trials Communications 4 (2016) 58e63625 mg twice daily and may be up-titrated to 7.5 mg tid or down-
titrated to 2.5 mg twice daily, if necessary. A starting dose of
2.5 mg twice daily may be recommended for older patients
[1,19]. As HR modulation in stable CAD provides no clinical
benefit, it is not necessary to reach a definite HR target.
3. When using ivabradine, attention should be paid to possible
drug interactions, and associations with diltiazem, verapamil or
strong inhibitors of CYP3A4 must be absolutely avoided.
4. Clinical examination at 3 months in patients receiving ivabra-
dine is useful for checking the effectiveness of treatment on
symptoms and its tolerance.
After SIGNIFY was published, regulatory authorities started a
procedure to assess the safety of ivabradine in patients with stable
CAD. However, there is a lot of data on the safety of the drug when
used in standard doses according to the indication approved by
regulatory authorities, derived from several clinical trials. Indeed,
these evaluated the safety of Ivabradine in patients with stable
angina, in patients with ischemic heart disease and left ventricular
dysfunction [3,9], and in patients with heart failure and severe LVD
[1,4,5,7].
Moreover, important insights about the efficacy and safety of
ivabradine are provided by AIFA (Agenzia Italiana del Farmaco)
real-world registry, collecting data from all online drugs pre-
scriptions made by Italian Cardiologists. From February 2008 to
October 2009, 14,256 patients were included. In this population,
the rates of serious adverse events were extremely low (0.4%), with
a rate of minor side effects (mainly phosphenes) lower than 1% and
an extremely low percentage of cardiovascular death (16 patients,
<0.1%). On the other hand, treatment with Ivabradine provided
excellent symptoms relief (angina reduced by 80% during obser-
vation period).
6. Conclusions
Despite a high HR being a risk marker in patients with stable
CAD and preserved left ventricular function, the pharmacological
modulation of heart rate obtained by adding ivabradine to standard
therapy does not provide significant prognostic benefits [14]. Given
that primary cardiovascular effect of Ivabradine is to reduce HR,
SIGNIFY suggests that an elevated HR is only a marker of risk e but
not a modifiable determinant of outcome-in patients who have
stable CAD without clinical HF.
Even in patients with CCS IIeIV angina, the clinical benefit of
Ivabradine is limited to symptoms relief and to reduced need for
revascularization, without any effect on prognosis; therefore,
reducing angina does not imply better outcome. These results are
not surprising: in stable CAD with preserved left ventricular func-
tion, all strategies aimed at symptoms relief (including PCI) did not
improve prognosis when added “on top” of secondary prevention
therapy (statins, antiplatelet agents, and ACE-inhibitors) [16,18].
Similarly to other clinical trials aimed at maximizing pharma-
cological intervention, findings from SIGNIFY confirms that “safety”
may be hampered by drug interactions and by unusual doses with
subsequent unexpected and confounding results [21e23].
The results of Signify will not modify the management of stable
angina in daily clinical practice or guidelines on this topic. In case of
preserved left ventricular function, ivabradine remains a “second-
line” drug for symptoms control, in addition to beta-blockers or
alternatively to them. In this context, coronary revascularization
should be considered only when medical therapy is ineffective or
partially effective; however, clinical efficacy should not be judged
on the basis of the achieved HR. In other words, there’s not enough
evidence for a strict HR target to reach in stable CAD, even if
SIGNIFY study does not denies in fact US guidelinesrecommendation of a HR target between 55 and 60 bpm [12,15].
In case of HF with severe LV dysfunction, when HR is still above
70 bpm, the combination of ivabradine with beta-blockers remains
strongly recommended, not only for symptoms relief, but to
improve prognosis [9,15].
After SIGNIFY it would be desirable to verify the effectiveness of
all drugs used in the treatment of stable angina without LV
dysfunction through prospective studies of appropriate size.
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